✦ LIBER ✦

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis

✍ Scribed by S.-M. Alavian; S. V. Tabatabaei; B. Behnava

Book ID: 108886668
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 198 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2011.01532.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact on adherence and sustained virolo

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C

✍ L. CASTERA; A. CONSTANT; C. HENRY; P. CHAMPBENOIT; P.-H. BERNARD; V. DE LEDINGHE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB

Mutation frequency of NS5A in patients v

Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy

✍ A. C. W. Jenke; S. Moser; V. Orth; M. Zilbauer; P. Gerner; S. Wirth 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

Peginterferon alfa-2a and ribavirin for

Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

✍ C. D. Howell; L. S. Jeffers; W. Cassidy; K. R. Reddy; S. Hu; J. S. Lee 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

A matched case-controlled study of 48 an

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72‐week PEG‐IFN/RBV and the predictive factors to such ther